Goldman Sachs Resumes Accretive Health (AH) at Neutral

Goldman Sachs transfers coverage on Accretive Health (NYSE: AH) and maintained a Neutral rating and $31 price target.

The firm said the company offers the highest EBITDA growth in their Healthcare coverage universe as they expect EBITDA to more than double by 2013E.

Commenting on the targeted customer base, Goldman notes "There are 2,055 (average 205 beds) hospitals in not-for-profit multi-hospital systems, suggesting a direct market opportunity of about $15 bn and a current market share of only 6%."

While Goldman is positive on the best-in-class product, receptive customers, and large total addressable markets, they are waiting for a better entry point.

For more ratings news on Accretive Health click here and for the rating history of Accretive Health click here.

Shares of Accretive Health closed at $27.31 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• DA Davidson Starts Everus (ECG) at Buy
• TD Cowen Assumes Incyte (INCY) at Buy
• Keefe, Bruyette & Woods Resumes Toronto-Dominion Bank (TD:CN) (TD) at Market Perform